 Connection
Margaret Macy to Antibodies, Monoclonal
This is a "connection" page, showing publications Margaret Macy has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.243 |
|
|
|
-
Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016 07; 62:9-17.
Score: 0.074
-
Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, Macy M, Bish J, Whitcomb P, Aikin A, Wright G, Yurasov S, Balis FM, Gore L. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res. 2011 Feb 01; 17(3):611-9.
Score: 0.051
-
Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys. 2009 Nov 15; 75(4):1148-54.
Score: 0.047
-
DuBois SG, Moreno L, Bagatell R, Cheung NK, Gray JC, Locatelli F, Reynolds CP, Rossig C, Sondel PM, Drezner N, Kholmanshikh O, Bird N, Day L, Ludwinski D, Scobie N, Pons Sanz V, Ball S, Hammer B, Alvarez Rojo I, Meager D, Sveistrup J, Berlanga P, Casanova M, Glade-Bender J, Macy M, Morgenstern DA, Owens C, Weigel BJ, Pappo A, Nysom K, Anderson J, Ligas F, Lesa G, Donoghue M, Karres D, Vassal G. Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer. Eur J Cancer. 2025 Dec 09; 231:116093.
Score: 0.036
-
Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG, Jonus HC, Shamirian A, Crowley M, Goodarzian F, Acharya PT, Pawel B, Erbe AK, Shahi A, Zaborek J, Kennedy E, Asgharzadeh S, Villablanca JG, Pinto N, Weiss BD, Mosse YP, Desai AV, Macy ME, Granger M, Vo KT, Sondel PM, Matthay KK, Park JR, Goldsmith KC. Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. J Clin Oncol. 2025 Aug; 43(22):2490-2501.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|